Literature DB >> 33989699

The role of GSK3 in metabolic pathway perturbations in cancer.

David Papadopoli1, Michael Pollak2, Ivan Topisirovic3.   

Abstract

Malignant transformation and tumor progression are accompanied by significant perturbations in metabolic programs. As such, cancer cells support high ATP turnover to construct the building blocks needed to fuel neoplastic growth. The coordination of metabolic networks in malignant cells is dependent on the collaboration with cellular signaling pathways. Glycogen synthase kinase 3 (GSK3) lies at the convergence of several signaling axes, including the PI3K/AKT/mTOR, AMPK, and Wnt pathways, which influence cancer initiation, progression and therapeutic responses. Accordingly, GSK3 modulates metabolic processes, including protein and lipid synthesis, glucose and mitochondrial metabolism, as well as autophagy. In this review, we highlight current knowledge of the role of GSK3 in metabolic perturbations in cancer.
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AMPK; Cancer; GSK3; Metabolism; mTOR

Year:  2021        PMID: 33989699     DOI: 10.1016/j.bbamcr.2021.119059

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Cell Res        ISSN: 0167-4889            Impact factor:   4.739


  4 in total

1.  Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 inhibitors.

Authors:  Amany Belal; Nagwa M Abdel Gawad; Ahmed B M Mehany; Mohammed A S Abourehab; Hazem Elkady; Ahmed A Al-Karmalawy; Ahmed S Ismael
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

2.  A Proteomic Platform Unveils the Brain Glycogen Phosphorylase as a Potential Therapeutic Target for Glioblastoma Multiforme.

Authors:  Giusy Ferraro; Matteo Mozzicafreddo; Roberta Ettari; Lorenzo Corsi; Maria Chiara Monti
Journal:  Int J Mol Sci       Date:  2022-07-25       Impact factor: 6.208

3.  Lithium Enhances Hippocampal Glucose Metabolism in an In Vitro Mice Model of Alzheimer's Disease.

Authors:  Camila Gherardelli; Pedro Cisternas; Nibaldo C Inestrosa
Journal:  Int J Mol Sci       Date:  2022-08-05       Impact factor: 6.208

4.  LRFN2 binding to NMDAR inhibits the progress of ESCC via regulating the Wnt/β-Catenin and NF-κB signaling pathway.

Authors:  Yu Zhou; Lijuan Xu; Jiru Wang; Beibei Ge; Qiuzi Wang; Tao Wang; Chang Liu; Bin Wei; Qilong Wang; Yong Gao
Journal:  Cancer Sci       Date:  2022-08-08       Impact factor: 6.518

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.